More evidence has emerged of appalling conflicts of interest that throw into doubt the advice rendered and the research performed by two prominent psychiatrists who have received substantial funding from the pharmaceutical industry. The revelations prove, once again, the need for universities and professional societies to crack down on conflicts of interest, and for Congress to pass legislation that will bring hidden conflicts into the open.
Earlier this year, Congressional investigators discovered that Dr. Joseph Biederman, a world-renowned child psychiatrist at Harvard Medical School and Massachusetts General Hospital, had failed to report to Harvard at least $1.4 million in income from drug companies, in violation of the university’s conflict-of-interest guidelines.
Now, internal drug company e-mail and documents that surfaced in a lawsuit have sketched out what looks like an unsavory collaboration between Dr. Biederman and Johnson & Johnson to generate and disseminate data that would support use of an antipsychotic drug, Risperdal, in children, a controversial target group.
The various documents indicate that Dr. Biederman repeatedly asked a Johnson & Johnson subsidiary to fund a research center at Massachusetts General to focus on children and adolescents with bipolar disorders and that the company provided almost $1 million. Disturbingly, one of the center’s publicly stated missions, along with improving the psychiatric care of children, was to “move forward the commercial goals of J.& J.”
http://www.nytimes.com/2008/11/30/opinion/30sun2.html?th&emc=th